Application of a 3D hydrogel-based model to replace use of animals for passaging patient-derived xenografts

In vitro models
S. J. Jones1, J. Ashworth2, Marian L Meakin3, Pamela Collier3, C. Probert3, Alison Ritchie3, Catherine L.R. Merry1, Anna Grabowska3
1Stem Cell Glycobiology Group, Biodiscovery Institute, University of Nottingham, Nottingham, UK
2School of Veterinary Medicine & Science, University of Nottingham, Nottingham, UK
3Ex Vivo Cancer Pharmacology Centre, Translational Medical Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK

Tóm tắt

Abstract Purpose This 3D in vitro cancer model for propagation of patient-derived cells, using a synthetic self-assembling peptide gel, allows the formation of a fully characterised, tailorable tumour microenvironment. Unlike many existing 3D cancer models, the peptide gel is inert, apart from molecules and motifs deliberately added or produced by cells within the model. Methods Breast cancer patient-derived xenografts (PDXs) were disaggregated and embedded in a peptide hydrogel. Growth was monitored by microscopic examination and at intervals, cells were extracted from the gels and passaged on into fresh gels. Passaged cells were assessed by qPCR and immunostaining techniques for the retention of characteristic markers. Results Breast cancer PDXs were shown to be capable of expansion over four or more passages in the peptide gel. Contaminating mouse cells were found to be rapidly removed by successive passages. The resulting human cells were shown to be compatible with a range of common assays useful for assessing survival, growth and maintenance of heterogeneity. Conclusions Based on these findings, the hydrogel has the potential to provide an effective and practical breast cancer model for the passage of PDXs which will have the added benefits of being relatively cheap, fully-defined and free from the use of animals or animal products. Encapsulated cells will require further validation to confirm the maintenance of cell heterogeneity, genotypes and phenotypes across passage, but with further development, including the addition of bespoke cell and matrix components of the tumour microenvironment, there is clear potential to model other cancer types.

Từ khóa


Tài liệu tham khảo

Okada S, Vaeteewoottacharn K, Kariya R. Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) Models. Cells. 2019;8(8):889.

Koga Y, Ochiai A. Systematic review of patient-derived xenograft models for preclinical studies of anti-cancer drugs in solid tumors. Cells. 2019;8(5):418.

Weeber F, et al. Tumor organoids as a pre-clinical cancer model for drug discovery. Cell Chem Biol. 2017;24(9):1092–100.

Romero-Calvo I, et al. Human organoids share structural and genetic features with primary pancreatic adenocarcinoma tumors. Mol Cancer Res. 2019;17(1):70–83.

Nelson SR, et al. Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line organoid development. Sci Rep. 2020;10(1):2778.

Nissen NI, Karsdal M, Willumsen N. Collagens and cancer associated fibroblasts in the reactive stroma and its relation to cancer biology. J Exp Clin Cancer Res. 2019;38(1):115.

Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–66.

Dekkers JF, et al. Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids. Nat Protoc. 2021;16(4):1936–65.

van de Wetering M, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161(4):933–45.

Hughes CS, Postovit LM, Lajoie GA. Matrigel: a complex protein mixture required for optimal growth of cell culture. Proteomics. 2010;10(9):1886–90.

Ashworth JC, et al. Peptide gels of fully-defined composition and mechanics for probing cell-cell and cell-matrix interactions in vitro. Matrix Biol. 2020;85–86:15–33.

James JR, et al. Hydrogel-based pre-clinical evaluation of repurposed FDA-approved drugs for AML. Int J Mol Sci. 2023;24(4):4235.

Mujeeb A, et al. Self-assembled octapeptide scaffolds for in vitro chondrocyte culture. Acta Biomater. 2013;9(1):4609–17.

Shinkai Y, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 1992;68(5):855–67.

Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007;7(2):118–30.

Eckhardt BL, et al. Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies. PLoS ONE. 2018;13(5):e0195932.

Pal A, et al. A 3D heterotypic breast cancer model demonstrates a role for mesenchymal stem cells in driving a proliferative and invasive phenotype. Cancers (Basel). 2020;12(8):2290.

Fong EL, et al. A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. Biomaterials. 2016;77:164–72.

Domenici G, et al. PDX-derived Ewing’s sarcoma cells retain high viability and disease phenotype in alginate encapsulated spheroid cultures. Cancers (Basel). 2021;13(4):879.

Onion D, et al. 3-Dimensional patient-derived lung cancer assays reveal resistance to standards-of-care promoted by stromal cells but sensitivity to histone deacetylase inhibitors. Mol Cancer Ther. 2016;15(4):753–63.

Hassani I, et al. Engineered colorectal cancer tissue recapitulates key attributes of a patient-derived xenograft tumor line. Biofabrication. 2022;14(4):045001.

Vinci M, et al. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol. 2012;10:29.

Hidalgo M, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998–1013.

Chao C, et al. Patient-derived xenografts from colorectal carcinoma: a temporal and hierarchical study of murine stromal cell replacement. Anticancer Res. 2017;37(7):3405–12.

Khalique L, et al. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol. 2007;211(3):286–95.

Ohlschlegel C, et al. HER2 genetic heterogeneity in breast carcinoma. J Clin Pathol. 2011;64(12):1112–6.

Gao Q, et al. Cell culture system for analysis of genetic heterogeneity within hepatocellular carcinomas and response to pharmacologic agents. Gastroenterology. 2017;152(1):232-242 e4.

Pauli C, et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 2017;7(5):462–77.

Neal JT, et al. Organoid modeling of the tumor immune microenvironment. Cell. 2018;175(7):1972-1988 e16.

Mazzucchelli S, et al. Establishment and morphological characterization of patient-derived organoids from breast cancer. Biol Proced Online. 2019;21:12.

Ashworth JC, et al. Preparation of a user-defined peptide gel for controlled 3D culture models of cancer and disease. J Vis Exp. 2020;166:e61710.

Schindelin J, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676–82.

Ealba EL, Schneider RA. A simple PCR-based strategy for estimating species-specific contributions in chimeras and xenografts. Development. 2013;140(14):3062–8.

Thông tin
Thông tin xuất bản

In vitro models

Thông tin tác giả